ClinicalTrials.gg
RecruitingNCT07374354Updated Jan 28, 2026

Preemptive Analgesia for Pain and Anxiety Control in Children With MIH

An interventional study of ibuprofen 100mg/ml oral suspension syrup and Placebo in Pain and Anxiety in Children With MIH, sponsored by October University for Modern Sciences and Arts. Recruiting at 1 site in Egypt. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by October University for Modern Sciences and Arts · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

This randomized, triple-blinded clinical trial aims to evaluate the effect of preemptive analgesia using ibuprofen on pain perception and anxiety during restorative treatment of first permanent molars in children diagnosed with molar-incisor hypomineralization (MIH). MIH-affected teeth often present with hypersensitivity, difficulty in achieving adequate anesthesia, and increased dental anxiety, which complicates dental treatment. Participants aged 6-12 years with MIH will receive either ibuprofen syrup or placebo 30 minutes before treatment. Pain will be assessed using the FLACC Behavioral Pain Scale and Wong-Baker FACES scale, and anxiety will be evaluated through heart rate and oxygen saturation. The results will determine whether preoperative ibuprofen reduces intraoperative pain and improves anxiety control in this population.

Read the detailed description

Molar-incisor hypomineralization (MIH) is a developmental enamel defect associated with post-eruptive breakdown, hypersensitivity, difficulty achieving effective anesthesia, increased dental anxiety, and a higher risk of restorative complications. Children with MIH require more frequent and complex dental care and often experience discomfort during treatment, negatively impacting their cooperation and oral-health-related quality of life.

Preemptive analgesia-the administration of analgesics before starting dental procedures-has shown promise in reducing nociceptive transmission and improving anesthetic efficacy. Previous studies have evaluated the effect of ibuprofen on pain during dental procedures in MIH-affected children, but evidence remains limited, and anxiety-related outcomes have not been comprehensively assessed.

This triple-blinded randomized controlled trial will include children aged 6-12 presenting with MIH and post-eruptive enamel breakdown but without carious lesions or prior restorations. Participants will be randomly assigned (1:1) to receive either ibuprofen 100 mg syrup or a matching placebo 30 minutes before treatment. All procedures will be performed under standardized conditions, including local anesthesia with articaine 4%, rubber dam isolation, and restorative treatment by trained pediatric dentists.

Pain perception will be recorded using both objective and subjective metrics. Objective pain will be evaluated using the FLACC Behavioral Pain Scale during anesthesia and treatment. Subjective pain will be assessed using the Wong-Baker FACES scale at predefined time points before, during, and after treatment. Dental anxiety will be monitored using physiological indicators: heart rate and oxygen saturation measured with a pulse oximeter at baseline, during, and after the dental procedure.

The primary objective is to determine whether preemptive ibuprofen reduces behavioral pain responses during treatment. Secondary objectives include assessing self-reported pain and physiologic anxiety measures. The findings aim to guide pediatric clinicians in improving pain control, reducing treatment-related anxiety, and enhancing the overall management of children with MIH.

02

Conditions studied

  • Pain and Anxiety in Children With MIH

Keywords

  • Molar Incisor Hypomineralization (MIH)
  • Preemptive Analgesia
  • Ibuprofen
  • Dental Pain
  • Dental Anxiety
  • FLACC Scale
  • Wong-Baker FACES
  • Post-Eruptive Enamel Breakdown
  • Children 6-12 Years
  • Analgesic Efficacy
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's planned enrollment of 46 is below the median of 66 across 8,493 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

October University for Modern Sciences and Arts is the lead sponsor of 51 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with molar incisor hypo-mineralization.
  2. Patient's age ranges from 6 to 12 years old.
  3. The affected tooth has demarcated opacity with post eruptive enamel breakdown.
  4. No cavitated lesion is related to the defect of previous restorative or preventive treatment.

Exclusion criteria

Exclusion Criteria:

  1. Children who are physically or mentally disabled or having any medical condition that will affect or complicate assessment of the intervention.
  2. Loss of tooth structure due to caries.
  3. intolerance to ibuprofen.
  4. developmental defects, including amelogenesis imperfecta and dentinogenesis imperfecta.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    ibuprofen 100mg/ml oral suspension syrup

    The analgesic will be labeled A; (ibuprofen 100 mg/ml oral suspension). Administration of analgesic will be 30 mins prior to procedure. The Operator who will perform the restorative treatment, the participant, and their guardian will not know which suspension will be administered (analgesic or placebo) or who analyzed the data. Only the professional who will administer the drug or placebo to the child and an external dental professional will know which will be used for each child, in case of any complications during the procedure. Local anesthesia administration using 1.8-mL of articaine 4% with epinephrine 1:100000. Rubber dam will be applied, then defect removal and cavity preparation and restorative treatment will be established.

    Drug: ibuprofen 100mg/ml oral suspension syrup

  • Placebo comparator
    placebo

    The placebo will be labeled B and will be sharing the same characteristics and flavor as the analgesic. Administration of placebo will be 30 mins prior to procedure. The Operator who will perform the restorative treatment, the participant, and their guardian will not know which suspension will be administered (analgesic or placebo) or who analyzed the data. Only the professional who will administer the drug or placebo to the child and an external dental professional will know which will be used for each child, in case of any complications during the procedure. Local anesthesia administration using 1.8-mL of articaine 4% with epinephrine 1:100000. Rubber dam will be applied, then defect removal and cavity preparation and restorative treatment will be established.

    Drug: Placebo

Interventions

  • Drugibuprofen 100mg/ml oral suspension syrup

    Drug page: Ibuprofen

    ibuprofen 100 mg/ml oral suspension administration 30 mins prior to procedure to assess the effect of preemptive analgesia on pain perception and anxiety management during restorative treatment of first permanent molars in children with molar incisor hypo-mineralization affected molars.

  • DrugPlacebo

    the placebo will be labeled B and will be sharing the same characteristics and flavor as the analgesic. Administration placebo will be 30 mins prior to procedure to assess the effect of preemptive analgesia on pain perception and anxiety management during restorative treatment of first permanent molars in children with molar incisor hypo-mineralization affected molars.

06

What researchers measure

Primary outcomes

  1. Pain perception (objective)

    Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Pain Scale. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2.

    Time frame: during injection and during procedure

Secondary outcomes

  1. pain perception (subjective)

    Wong Baker FACES Pain Rating Scale. It consists of several faces ranging from happy (0) to crying (10).

    Time frame: Initial before procedure (baseline) After drug/placebo administration (30 min), Before anesthesia, After anesthesia, During the procedure (real-time) 24 hours after the end of the procedure (post-operative)

  2. dental anxiety

    pulse oximeter (heart rate monitor) unit: Beat/ minute

    Time frame: initial before treatment (baseline), during anesthesia, during treatment (real-time) and immediately after treatment (post-operative)

  3. dental anxiety

    pulse oximeter oxygen saturation unit: percentage

    Time frame: initial before treatment (baseline), during anesthesia, during treatment (real-time) and immediately after treatment (post-operative)

07

Study locations

1 of 1 sites recruiting
  • October university of modern science and arts
    Giza, 12611, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07374354
Lead sponsor
October University for Modern Sciences and Arts
Responsible party
Esraa Diaaeldin Nady Elhenie (general practitioner, October University for Modern Sciences and Arts) — Principal investigator
First posted
Jan 28, 2026
Start date
Feb 2026 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Jan 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion